ABG Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Scale And Distribution FranchiseCencora’s large-scale distribution and integrated pharma services provide durable competitive advantages: purchasing leverage, logistics scale, and deep manufacturer and provider relationships. This scale lowers per-unit costs, supports contract wins, and creates high switching frictions for customers over months to years.
Gross Profit And Margin ExpansionSustained gross-profit growth and margin improvement indicate durable mix gains from specialty businesses (including OneOncology) and improved pricing/operations. For a low-margin distribution model, incremental margin expansion materially boosts operating income sustainability and buffers against cyclical revenue declines.
Strong Cash Generation And Capital ReturnsRobust quarterly free cash flow, a $3.0B FCF target and a $1B repurchase plan demonstrate durable cash-generation capacity. Consistent FCF enables debt paydown, selective M&A and shareholder returns, supporting long-term value creation even while managing capital for integration and growth.
Bears Say
Elevated LeverageHigh debt relative to equity constrains strategic flexibility and raises sensitivity to interest-cost increases. Elevated leverage reduces the company’s buffer against revenue or margin shocks, limits ability to fund large acquisitions without refinancing, and prolongs the timeline to reach a conservative capital structure.
Declining Trailing Free Cash FlowA meaningful TTM free-cash-flow decline signals higher working-capital demands or timing pressures in distribution. Persistently lower FCF would slow deleveraging, restrict buybacks and limit reinvestment, reducing resilience against sector headwinds and making capital allocation tougher over the medium term.
Structural Revenue HeadwindsSustained revenue pressure from manufacturer list-price cuts, customer account losses, and faster mail-order conversions can persistently depress top-line volume in a low-margin business. Given limited margin cushions, prolonged top-line weakness would strain operating-leverage dynamics and complicate earnings durability.
Cencora News
ABG FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Cencora, Inc.’s market cap?
Currently, no data Available
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 36 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on May 06, 2026. The company reported $3.797 earnings per share for the quarter, missing the consensus estimate of $3.851 by -$0.054.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. does not currently pay dividends.
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 3.48.
How many shares outstanding does Cencora, Inc. have?
Currently, no data Available
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of $3.797 in its last earnings report, missing expectations of $3.851. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in CH:ABG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$280.23 (― Downside)
$280.23 (― Downside)
Insider Transactions
Bought Shares
Worth CHF1.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.79%
12-Months-Change
Fundamentals
Return on Equity
115.93%
Trailing 12-Months
Asset Growth
14.69%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
ABG Company Deck
ABG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong profitability and cash-generation metrics (EPS growth +7.5%, gross profit +16%, operating income +6%), a raised EPS range, improved operating income guidance, robust international performance, and the resumption of $1B share repurchases against material near-term revenue pressures (reduced consolidated revenue guidance from 7%–9% to 4%–6%) driven by WAC price reductions, account losses and faster mail-order brand conversions. Management highlighted transitory items (weather, COVID vaccine comparisons) and acquisition-related expense impacts but maintained confidence in long-term operating income growth and free cash flow generation.View all CH:ABG earnings summariesABG Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations
ABG Stock 12 Month Forecast
Average Price Target
$280.23
Options Prices
Currently, No data available
---